ReviewCurrent atherosclerosis reports2019
Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials.
Review in Current atherosclerosis reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Effect of n-3 polyunsaturated fatty acids on ischemic heart disease and cardiometabolic risk factors: a two-sample Mendelian randomization study.BMC cardiovascular disorders · 2021Trial
- Regular use of fish oil supplements and course of cardiovascular diseases: prospective cohort study.BMJ medicine · 2024Article
- Plasma Cholesterol- and Body Fat-Lowering Effects of Chicken Protein Hydrolysate and Oil in High-Fat Fed Male Wistar Rats.Nutrients · 2022Article
- Exploring the therapeutic potential of omega-3 fatty acids in depression.Environmental science and pollution research international · 2021Review
- Bladder Hyperactivity Induced by Oxidative Stress and Bladder Ischemia: A Review of Treatment Strategies with Antioxidants.International journal of molecular sciences · 2021Review
- The Truth About Fish (Oil) in the Treatment of Dyslipidemia.Current atherosclerosis reports · 2021Review
- Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session.Current atherosclerosis reports · 2020Review
- Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions.Current atherosclerosis reports · 2020Review
- Omega-3 PUFA Responders and Non-Responders and the Prevention of Lipid Dysmetabolism and Related Diseases.Nutrients · 2020Review
- Diet and lifestyle considerations for patients with prostate cancer.Urologic oncology · 2020Review
- Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions.Current atherosclerosis reports · 2020Review
- Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date.Vascular health and risk management · 2020Review
- Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session.Current atherosclerosis reports · 2019Review
- A Review of Oxidative Stress and Urinary Dysfunction Caused by Bladder Outlet Obstruction and Treatments Using Antioxidants.Antioxidants (Basel, Switzerland) · 2019Review
- Effect of linoleic acid on ischemic heart disease and its risk factors: a Mendelian randomization study.BMC medicine · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewOmega-3 fatty acids (ω-3 FA) are among the most well-recognized health supplements but their cardiovascular benefits have long been controversial owing to inconsistent results from previous cardiovascular outcomes trials (CVOT). In this article, we provide a short review of existing literature followed by recent randomized clinical trial data, with a discussion of the potential clinical implications of these new findings. RECENT
findingsData from the randomized, controlled trial REDUCE-IT, when viewed within the context of other recently published trials ASCEND and VITAL, add to a growing body of evidence on the use of ω-3 FA therapies in the treatment of atherosclerotic cardiovascular disease (ASCVD). Given the different formulations, dosages, and patient populations studied, CVOTs of ω-3 FA have provided valuable insight into the use of these agents in cardioprotection. Current data suggest that higher dosages of pure eicosapentaenoic acid ω-3 FA formulations provide additional benefit in reduction of ASCVD events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.